XML 25 R18.htm IDEA: XBRL DOCUMENT
v3.26.1

Stockholders' Equity | 6 Months Ended
--- | ---
Jun. 30, 2026
Stockholders Equity Note [Abstract] |
Stockholders' Equity | NOTE 9 – STOCKHOLDERS’ EQUITY The Company’s amended and restated certificate of incorporation, filed with the Delaware Secretary of State on February 2, 2018, authorizes the Company to issue 10,000,000 shares of preferred stock and 50,000,000 shares of common stock. 2017 Equity Incentive Plan On October 10, 2017, the Company’s board of directors approved and adopted the Company’s 2017 Equity Incentive Plan (as amended to date, the “2017 Plan”), subject to stockholder approval thereof. On December 18, 2017, the Company’s stockholders approved the 2017 Plan. The 2017 Plan allows for the grant of a variety of equity vehicles to provide flexibility in the grant and issuance of equity awards, including stock options, unrestricted stock grants, restricted stock units (“RSUs”), stock bonuses and performance-based awards. An aggregate of 1,500,000 shares of common stock were initially reserved for issuance under the 2017 Plan. The number of shares authorized for issuance under the 2017 Plan was increased to 3,000,000 shares on May 19, 2021; increased to 5,000,000 shares on May 15, 2024; and further increased to 7,000,000 shares on May 13, 2026. As of June 30, 2026, 2,617,779 shares remain available for future issuance under the 2017 Plan. Executive Employment Agreements On June 5, 2023, in connection with, and as a material inducement to, the appointment of Michael Knowles as the Company’s new chief executive officer and president, Mr. Knowles was granted (i) non-qualified stock options to purchase 400,000 shares of Company common stock (the “Inducement Options”), which Inducement Options have an exercise price equal to $2.95 per share and will expire ten years from the date of the grant; and (ii) 400,000 restricted stock units (together with the Inducement Options, the “Inducement Grants”). Both of the Inducement Grants shall vest over a four-year period as follows: 25% on the one-year anniversary of the date of the grant, and the remaining 75% will vest in six equal installments, commencing six months after the one-year anniversary of the date of grant and every six months thereafter until fully vested, subject to Mr. Knowles’ continued employment by the Company. The Inducement Grants were granted outside of the Company’s 2017 Plan and any other equity incentive plans, and in reliance on the employment inducement exemption provided under the Nasdaq Listing Rule 5635(c)(4). Stock Options A summary of stock option activity under the Company’s current equity incentive plans during the six month period ended June 30, 2026, was as follows:
|  | Stock Options Outstanding |
|  | Number of Underlying Shares |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Life (in years) |  |  | Aggregate Intrinsic Value |
Outstanding on January 1, 2026 |  |  | 621,539 |  |  | $ | 2.81 |  |  |  | 5.37 |  |  | $ | 9,705,525 |
Granted |  |  | - |  |  | $ | - |  |  |  | - |  |  |  | - |
Forfeited / Canceled |  |  | (9,315 | ) |  | $ | 1.19 |  |  |  | - |  |  |  | (328,112 | )
Exercised |  |  | (60,649 | ) |  | $ | 3.13 |  |  |  | - |  |  | $ | (912,698 | )
Outstanding on June 30, 2026 |  |  | 551,575 |  |  | $ | 2.83 |  |  |  | 5.39 |  |  | $ | 8,464,716 |
Exercisable as of June 30, 2026 |  |  | 451,575 |  |  | $ | 2.81 |  |  |  | 5.05 |  |  | $ | 6,941,716 |
As of June 30, 2026, there was $185,033 of unrecognized compensation expense related to unvested stock options, which is expected to be recognized over a weighted average period of 0.47 years. There were no options granted during the three or six month periods ended June 30, 2026 or 2025. The following table presents the grant date fair value of options vested and the intrinsic value of options exercised:
|  | For the Six Months Ended June 30, |
|  | 2026 |  |  | 2025 |
Grant date fair value of options vested |  | $ | 760,142 |  |  | $ | 688,212 |
Intrinsic value of options exercised |  | $ | 912,698 |  |  | $ | 479,040 |
If there are any modifications or cancellations of the underlying unvested awards, the Company may be required to accelerate, increase, or cancel any remaining unearned stock-based compensation expense or calculate and record additional expense. Future stock-based compensation expense and unearned stock-based compensation will increase to the extent that the Company grants additional common stock options or other stock-based awards. Restricted Stock Units RSUs may be granted at the discretion of the compensation committee of the Company's board of directors under the 2017 Plan in connection with the hiring and retention of personnel and are subject to certain conditions. RSUs generally vest quarterly or semi-annually over a period of one to three years and are typically forfeited if employment is terminated before the RSUs vest. The compensation expense related to the RSUs is calculated as the fair value of the common stock on the grant date and is amortized to expense over the vesting period and is adjusted for forfeitures. The Company’s RS U activity for the six months ended June 30, 2026, was as follows:
|  | Restricted Stock Units |
|  | Number of Underlying Shares |  |  | Weighted Average Grant Date Fair Value |
Unvested on January 1, 2026 |  |  | 997,647 |  |  | $ | 3.32 |
Granted |  |  | 484,743 |  |  | $ | 10.34 |
Vested |  |  | (410,070 | ) |  | $ | 3.19 |
Canceled |  |  | (26,136 | ) |  | $ | 3.18 |
Unvested on June 30, 2026 |  |  | 1,046,184 |  |  | $ | 6.62 |
As of June 30, 2026, there was $5,904,932 of unrecognized compensation expense related to unvested RSUs, which is expected to be recognized over a weighted average period of 1.06 years. Stock-based compensation expense associated with continuing operations for the three and six month periods ended June 30, 2026 and 2025, was comprised of the following:
|  | For the Three Months Ended June 30, |  |  | For the Six Months Ended June 30, |
Stock-based compensation classified as: |  | 2026 |  |  | 2025 |  |  | 2026 |  |  | 2025 |
General and administrative |  | $ | 557,051 |  |  | $ | 323,327 |  |  | $ | 962,411 |  |  | $ | 731,573 |
Production |  |  | 53,304 |  |  |  | 21,906 |  |  |  | 92,744 |  |  |  | 43,327 |
Marketing and selling |  |  | 179,704 |  |  |  | 89,312 |  |  |  | 325,141 |  |  |  | 181,082 |
Research and development |  |  | 71,154 |  |  |  | 48,805 |  |  |  | 136,045 |  |  |  | 105,773 |
|  | $ | 861,213 |  |  | $ | 483,350 |  |  | $ | 1,516,341 |  |  | $ | 1,061,755 |
Stock-based compensation expense associated with discontinued operations for the three month periods ended June 30, 2026 and 2025 was $0 and $32,424, respectively. Stock-based compensation expense associated with discontinued operations for the six month periods ended June 30, 2026 and 2025 was $0 and $66,580, respectively. Warrants The Company did no t have any outstanding warrants as of June 30, 2026 or December 31, 2025.

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration